RankingsPricing
  1. US-listed companies
  2. VERTEX PHARMACEUTICALS INC
  3. Financials
  4. Net income

VERTEX PHARMACEUTICALS INCVRTX

Market cap
$109.6B
P/E ratio
SummaryFinancials
Period EndNet income (Million USD)YoY (%)
Dec 31, 2024-536-114.80%
Dec 31, 20233,620+8.96%
Dec 31, 20223,322+41.84%
Dec 31, 20212,342-13.63%
Dec 31, 20202,712+130.42%
Dec 31, 20191,177-43.88%
Dec 31, 20182,097+695.83%
Dec 31, 2017263-413.56%
Dec 31, 2016-84-84.90%
Dec 31, 2015-556-24.67%
Dec 31, 2014-739+65.96%
Dec 31, 2013-445+770.30%
Dec 31, 2012-51-224.18%
Dec 31, 201141-105.46%
Dec 31, 2010-755

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating income Operating expenses Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSAdjusted EPSDividend payout ratio (%)Dividend per shareAdjusted DPSEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)